CClinicalTrials.gg
CompletedNCT03306381Updated Dec 10, 2019

The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS

An interventional study of Dietary intervention in IBS - Irritable Bowel Syndrome, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Region Skane · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the present study is to research whether subjects with irritable bowel syndrome (IBS) display epigenetic/genetic changes or altered microbiota compared to a non-IBS control group. Further, we will investigate if these parameters as well as subjective IBS symptoms are affected by a 4-week long dietary intervention within the IBS patient group.

Read the detailed description

The study will be performed on 140 subjects with verified IBS. Patients will be recruited from the clinic of Gastroenterology or Internal medicine as well as primary health care centers. At the start of the study patients will fill out protocols concerning Rom IV criteria (to validate that IBS criteria are filled) as well as IBS symptom rating scales. They will be examined by a physician/researcher who will complete protocols of clinical data. Blood and fecal samples will be collected. A control group of healthy, non-IBS individuals will go through the same procedure as described above.

Study participants with IBS will thereafter be randomized to receive an alternative diet resembling the FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) diet (n=130), or to continue with their regular diet (control group; n=20). After 4 weeks of dietary intervention, there will be a follow-up where blood and fecal samples are once again collected. At this point in time, participants will also fill in IBS symptom rating scales again.

Samples from baseline and 4 weeks will be used for genetic/epigenetic (including genomic-wide association studies), gut microbiota and inflammatory parameter analyses.

Statistics

To study differences in the above-mentioned parameters between patients and controls as well as before and after dietary intervention, Mann-Whitney U-test and Wilcoxon test will be used, respectively.

02

Conditions studied

  • IBS - Irritable Bowel Syndrome

Keywords

  • IBS
  • Epigenetics
  • Dietary intervention
  • Gut Microbiota
  • Inflammation
  • Genetics
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Verified IBS according to Rom IV criteria.

Exclusion criteria

Exclusion Criteria:

  • Serious mental or somatic disease
  • Abuse
  • Inability to understand he Swedish language
  • Already on a diet (e.g. vegan, FODMAP, gluten-free).
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Dietary intervention subject group

    n=130. Participants on low FODMAP-similar diet during 4-week study period.

    Other: Dietary intervention

  • No intervention
    Control group

    n=20. Participants on traditional IBS diet during 4-week study period.

Interventions

  • OtherDietary intervention

    Elimination of certain products.

05

What researchers measure

Primary outcomes

  1. Genetic variation of enzymes regulating absorption of disaccharides

    Genetic expression of disaccharide-degradating enzymes will be measured at baseline and related to the response of study participants to dietary intervention.

    Time frame: measured at baseline

Secondary outcomes

  1. Irritable bowel syndrome-subjective severity scores (IBS-SSS) ratings

    Changes from baseline in subjective symptoms according to the IBS-SSS.

    Time frame: 4 weeks

  2. Visual analog scale for irritable bowel syndrome (VAS-IBS) ratings

    Changes from baseline in subjective symptoms according to the VAS-IBS.

    Time frame: 4 weeks

  3. Gut microbiota composition

    Changes from baseline in fecal microbiota analysed by 16rs

    Time frame: 4 weeks

  4. Cytokines

    Changes from baseline in cytokine plasma concentrations will be assessed by ELISA.

    Time frame: 4 weeks

  5. microRNA expression

    Changes from baseline in microRNA expression will be assessed.

    Time frame: 4 weeks

06

Study locations

1 site
  • Deartment of INternal Medicine
    Malmö, 20502, Sweden
07

References and documents

Publications

  • Nilholm C, Manoharan L, Roth B, D'Amato M, Ohlsson B. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022 May;10(4):363-375. doi: 10.1002/ueg2.12227. Epub 2022 Apr 28. PubMed 35484927 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03306381
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Oct 11, 2017
Start date
Jan 15, 2018
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019
Last update
Dec 10, 2019

Study contacts

Bodil Ohlsson, MD, PhD
principal investigator · Region Skane

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion